| Name | Title | Contact Details |
|---|---|---|
Anurag Dhingra |
Chief Technology Officer | Profile |
People always ask, what does strategic communications mean? For us, it means finding interesting, smart, and inventive ways to get information to the right people. It means streamlining programs that are cumbersome, messy, and confusing and making them easy to use. It means identifying dated layout and design and creating content that is stunning and engaging. Based in Natick, MA, Strategic Communications, Inc. (StratComm) has served the marketing, communications, training, and project management needs of nationwide Fortune 500 companies, many federal agencies, and all branches of the Armed Forces for over 45 years. Our team works with a variety of clients and delivers an array of services. We create high-quality publications, both print and electronic, and training platforms for leading corporations and organizations such as IBM, VMware, the United States Navy and Air Force, the U.S. Department of State, Veterans Affairs, the U.S. Treasury, and many other important agencies and organizations. We also manage large programs for the federal government utilizing emerging technologies. Two examples are online training and testing programs for U.S. Embassies worldwide and program management for the Social Security Administration. Many high profile clients contract with StratComm to update the design and content of their websites, brochures, annual reports, and web apps. Our team is constantly seeking newer technologies and developing efficiencies to better serve our clients. Within our headquarters, we house a core team of dedicated professionals who administer our programs. Together, we manage varied projects and communications challenges for both large and small clients. Strategically, of course.
Global Synergizers is a social impact consulting firm that collaborates with corporates, social product innovators and social organisations to enable collective impact. Our programs are aligned with UN SDGs and address issues at the local level to create a systemic effect. If you would like to collaborate with us, write to us on info@globalsynergizers.com.
DGA Group is a global advisory firm that helps clients protect – and grow – what they have built in todays complex business environment. We understand the challenges and opportunities in an increasingly regulated and interconnected world. Leveraging the expertise and experience of our team at Albright Stonebridge Group, a leader in global strategy and commercial diplomacy, and a deep bench of communications, public affairs, government relations and business intelligence consultants, we help clients navigate and shape global policy, reputational and financial issues.
Sycamore is a specialty wholesale broker, focusing on hospitality, cannabis, energy and niche personal lines dwellings. Sycamore Specialty Underwriters started its wholesale broker operations in 2014. Partnering with insurance companies around the country, Sycamores goal is to make sure agents seeking specialized products have a one stop-shop to finding coverage for their clients.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.